Publications by authors named "Karolin Romahn"
Pharmaceutics
October 2023
Article Synopsis
- Regulatory agencies require that drug-drug interactions (DDIs) are evaluated during drug development to ensure safety and efficacy, but testing all interactions isn’t practical due to time and cost constraints.
- A physiologically based pharmacokinetic (PBPK) model was created using GastroPlus to study the effects of phenytoin, which can both induce and be affected by different liver enzymes (CYP3A4, CYP2C9, and CYP2C19).
- The PBPK model accurately predicted phenytoin's behavior in the body based on various doses and conditions, thereby demonstrating its potential in assessing DDIs with other drugs like fluconazole and omeprazole, which can help streamline drug development processes.
